SCHEMBL3493372

SCHEMBL3493372

Cc1c(C(=O)O)sc2nc(C(c3ccccc3)c3ccccc3)[nH]c(=O)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.53
TDP1 Q9NUW8 6/20 0.52
BCAT2 O15382 1/20 0.49
ALDH1A1 P00352 7/20 0.48
KMT2A Q03164 6/20 0.48
KDM4E B2RXH2 2/20 0.48
MAPT P10636 5/20 0.47
MEN1 O00255 5/20 0.47
HPGD P15428 2/20 0.47
APEX1 P27695 1/20 0.47
RECQL P46063 1/20 0.47
MCL1 Q07820 1/20 0.47
TSHR P16473 2/20 0.47
GAA P10253 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
LMNA P02545 1/20 0.45
ALPL P05186 1/20 0.45
RAB9A P51151 1/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4592756 0.89 POLB (0.46) POLBTDP1BCAT2ALDH1A1KMT2A
SCHEMBL3494438 0.89 POLB (0.52) POLBTDP1BCAT2ALDH1A1KMT2A
SCHEMBL4520199 0.87 KMT2A (0.63) POLBALDH1A1KMT2AKDM4EMAPT
SCHEMBL3491840 0.79 ALDH1A1 (0.62) POLBTDP1BCAT2ALDH1A1KMT2A
SCHEMBL3491512 0.78 POLB (0.48) POLBTDP1BCAT2ALDH1A1KMT2A
SCHEMBL13341339 0.78 ALDH1A1 (0.75) POLBTDP1ALDH1A1KMT2AKDM4E
SCHEMBL4520492 0.77 KMT2A (0.62) POLBALDH1A1KMT2AKDM4EMAPT
SCHEMBL3493547 0.76 TDP1 (0.52) POLBTDP1BCAT2ALDH1A1KMT2A
SCHEMBL3494356 0.76 TSHR (0.57) POLBTDP1BCAT2ALDH1A1KMT2A
SCHEMBL3492121 0.76 ADORA3 (0.55) POLBTDP1BCAT2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD POLB 555/4885TDP1 409/4885BCAT2 2012/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 POLB 1353/4885TDP1 1594/4885BCAT2 1139/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 POLB 2134/4885TDP1 76/4885BCAT2 1726/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 POLB 2134/4885TDP1 76/4885BCAT2 1726/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 POLB 1353/4885TDP1 1594/4885BCAT2 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.